Skip to main content

Advertisement

Table 2 Overall survival data

From: Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer

Outcome (n, %) Survival (months) p-value HR (95% CI) p-value
≥30% PSA response at 4 weeks (97)
 Yes (38, 39.2) 40.0 (23.9–55.0) 0.014 0.54 (0.33–0.89) 0.015
 No (59, 60.8) 19.7 (16.0–25.1)
≥50% PSA response at 4 weeks (97)
 Yes (32, 33.0) 41.1 (23.2-NE) 0.007 0.49 (0.28–0.83) 0.006
 No (65, 67.0) 19.9 (16.0–26.1)
≥30% PSA response at 8 weeks (95)
 Yes (46, 48.4) 40.0 (25.1–48.4) 0.004 0.51 (0.32–0.82) 0.005
 No (49, 51.6) 18.7 (16.0–23.9)
≥50% PSA response at 8 weeks (95)
 Yes (35, 36.8) 37.4 (23.9–46.0) 0.058 0.62 (0.38–1.02) 0.054
 No (60, 63.2) 20.3 (17.8–26.1)
≥30% PSA response at 12 weeks (93)
 Yes (51, 54.8) 35.2 (24.0–45.7) 0.017 0.56 (0.35–0.91) 0.019
 No (42, 45.2) 18.6 (13.4–23.9)
≥50% PSA response at 12 weeks (93)
 Yes (40, 43.0) 40.0 (26.1–55.0) 0.002 0.47 (0.29–0.77) 0.002
 No (54, 57.0) 19.6 (15.0–23.9)
  1. Data from Kaplan Meyer and univariate cox regression analyses for a PSA response ≥30% and ≥ 50% at four, eight, and twelve weeks. Median survival is presented in months (95% CI). NE = not evaluable. P-values in bold text are statistically significant (p ≤ 0.05)